This is a summary of the European public assessment report (EPAR) for Pemetrexed Fresenius Kabi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pemetrexed Fresenius Kabi. For practical information about using Pemetrexed Fresenius Kabi, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
**Malignant pleural mesothelioma** Pemetrexed Fresenius Kabi in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. **Non\-small cell lung cancer** Pemetrexed Fresenius Kabi in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non\-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Fresenius Kabi is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non\-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum\-based chemotherapy. Pemetrexed Fresenius Kabi is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non\-small cell lung cancer other than predominantly squamous cell histology.
Therapeutic Area (MeSH)
ATC Code
L01BA04
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| pemetrexed | N/A | pemetrexed |
EMA Name
Pemetrexed Fresenius Kabi
Medicine Name
Pemetrexed Fresenius Kabi
Aliases
N/ANo risk management plan link.
